PeproMene Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.pepromenebio.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-NHL
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- PeproMene Bio, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05370430
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Atrium Health Levine Cancer Institute - Morehead, Charlotte, North Carolina, United States
🇺🇸Providence Swedish Cancer Institute, Seattle, Washington, United States
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- PeproMene Bio, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04690595
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
News
PeproMene Bio's BAFFR-CAR T Cell Therapy Shows Promise in Relapsed B-ALL Trial
PeproMene Bio reports complete remission in the first patient treated with PMB-CT01 (BAFFR-CAR T cells) for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).